JPRN-UMIN000027224
Completed
未知
The effects of Teneligliptin on vascular inflammatory markers in post-PCI (Percutaneous Coronary Intervention) patients. - The effects of Teneligliptin on vascular inflammatory markers in post-PCI (Percutaneous Coronary Intervention) patients.
Kameda Medhical Center0 sites20 target enrollmentMay 2, 2017
ConditionsCoronary Artery Disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Coronary Artery Disease
- Sponsor
- Kameda Medhical Center
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\)Patients with T1DM (type 1 diabetes mellitus) 2\)Patients who have medical history of hypersensitivity to diabetes mellitus drugs 3\)Patients with medical history of malignant tumor 4\)Patients with severe infection, before and after operation, or severe trauma 5\)Patients with cardiac arrest (class of III in NYHA) 6\)Patients with uncontrolled hypertension 7\)Patients with insulin dependent and the potential to change diabetic drugs 8\)Patients with severe renal insufficiency (eGFR is less than 30 mL / min / 1\.73 m2, dialysis\-dependent, or serum creatinine (men, more than 2\.5 mg / dL, women, more than 2\.0 mg / dL 9\) Patients with pregnant, and possibly pregnant 10\) Patients with severe ketosis, diabetic coma, or history of coma within the past six months 11\)Patients who had stroke, cerebral hemorrhage, subarachnoid hemorrhage, or transient ischemic attack within the past three months. 12\)Patients who enrolled into another clinical test within three months prior to this trial 13\)Patients who cannot administer antiplatelet drugs 14\)Patients who were considered as inappropriate for the study by the investigator.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
The effects of Teneligliptin on endothelial function in type 2 diabetes mellitus with chronic kidney diseaseType 2 diabetes mellitus with chronic kidney diseaseJPRN-UMIN000017180Dokkyo Medical University50
Completed
Not Applicable
Effect of teneligliptin on endothelial dysfunction induced by postprandial hypelipidemiaMetabolic syndromeJPRN-UMIN000012588Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences20
Not yet recruiting
Not Applicable
Effects of teneligliptin for atherosclerosis-related biomarkers in patients with type 2 diabetes mellitusJPRN-UMIN000009905First Department of internal Medicine, Kansai Medical University60
Completed
Not Applicable
The effect of trelagliptin on vascular endothelial functions in patients with type II diabetes mellitus.Patients with type 2 diabetesJPRN-UMIN000018311Ise Red Cross Hospital Department of Metabolic Diseases30
Active, not recruiting
Not Applicable
Effect of Linagliptin on vascular inflammation in patients with type 2 diabetes mellituspatients with type 2 diabetes mellitus and vascular inflammationMedDRA version: 17.0Level: PTClassification code 10061218Term: InflammationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 17.0Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2012-003859-12-DERWTH Aachen University for the Medical Faculty, represented by Clinical Trial Center Aachen (CTC-A)60